최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, v.23 no.12, 2011년, pp.1098 - 1104
Lee, K. J. (Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea) , Kim, N. Y. (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea) , Kwon, J. K. (Department of Internal Medicine, Daeku Catholic University College of Medicine, Daeku, Korea) , Huh, K. C. (Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea) , Lee, O. Y. (Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea) , Lee, J. S. (Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea) , Choi, S. C. (Department of Internal Medicine, Wonkwang University College of Medicine, Iksan, Korea) , Sohn, C. I. (Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul, Korea) , Myung, S. J. (Department of Internal Medicine, Ulsan University College of Medicine, Ulsan, Korea) , Park, H. J. (Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea kn<) , Choi, M. K. , Bak, Y. T. , Rhee, P. L.
AbstractBackground The 5‐HT3 receptor antagonists are known to be effective for the treatment of diarrhea‐predominant irritable bowel syndrome (IBS), but not widely used yet. The aim of this study was to compare the efficacy and safety of ramosetron, a 5‐HT3 receptor antagoni...
Croghan Recognizing and managing patients with irritable bowel syndrome J Am Acad Nurse Pract 2005 10.1111/j.1041-2972.2005.00011.x 17 51
Wilson Prevalence of irritable bowel syndrome: a community survey Br J Gen Pract 2004 54 495
Gwee The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community Am J Gastroenterol 2004 10.1111/j.1572-0241.2004.04161.x 99 924
Saito The epidemiology of irritable bowel syndrome in North America: a systematic review Am J Gastroenterol 2002 97 1910
Camilleri Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial Lancet 2000 10.1016/S0140-6736(00)02033-X 355 1035
Cremonini Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials Neurogastroenterol Motil 2003 10.1046/j.1365-2982.2003.00389.x 15 79
Camilleri A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome Arch Intern Med 2001 10.1001/archinte.161.14.1733 161 1733
Miyata Involvement of the 5-HT3 receptor in CRH-induce defecation in rats Am J Physiol 1998 274 G827
Hirata Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents J Pharmacol Sci 2008 10.1254/jphs.FP0071943 106 264
Hirata Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer Neurogastroenterol Motil 2008 10.1111/j.1365-2982.2007.01069.x 20 557
Matsueda A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome Digestion 2008 10.1159/000150632 77 225
Matsueda A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome Scand J Gastroenterol 2008 10.1080/00365520802240255 43 1202
Jones Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients Aliment Pharmacol Ther 1999 10.1046/j.1365-2036.1999.00678.x 13 1419
Darvish-Damavandi A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome World J Gastroenterol 2010 10.3748/wjg.v16.i5.547 16 547
Longstreth Functional bowel disorders Gastroenterology 2006 10.1053/j.gastro.2005.11.061 130 1480
Rabasseda Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting Drugs Today 2002 10.1358/dot.2002.38.2.820104 38 75
Gan Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs 2005 10.2165/00023210-200519030-00004 19 225
Andresen Effects of 5-HT3 antagonists on symptom relief and constipation in non-constipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Clin Gastroenterol Hepatol 2008 10.1016/j.cgh.2007.12.015 6 545
Rahimi Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12-week trials Clin Ther 2008 10.1016/j.clinthera.2008.05.002 30 884
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.